Daré Bioscience, Inc.

Contributing Author

Recent Articles by Daré Bioscience, Inc.

Aug-31	Dare Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth DARE GlobeNewswire
Aug-27	Dare Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor "Why Now" On-Demand Series DARE GlobeNewswire
Aug-26	Dare Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society DARE -8.54% GlobeNewswire
Aug-25	Dare Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment DARE GlobeNewswire
Aug-18	DARE Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 "50 Over 50: Innovation" List DARE -5.18% GlobeNewswire
Aug-18	DARE Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 "50 Over 50: Innovation" List DARE -5.18% GlobeNewswire
Aug-14	Dare Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules DARE -32.12% DARE -12.88% GlobeNewswire
Aug-13	Dare Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances DARE GlobeNewswire
Aug-06	Dare Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 DARE GlobeNewswire
Jul-28	Dare Bioscience Expands Access Options for DARE to PLAY and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx DARE -10.23% GlobeNewswire
Jul-20	Dare Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities DARE -31.63% GlobeNewswire
Jul-09	Dare Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event DARE GlobeNewswire
Jul-01	Dare Bioscience Announces Flora Sync LF5 Is Now Available Through Its Direct-to-Consumer Platform DARE GlobeNewswire
Jun-25	Dare Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5 in Virtual Investor "What This Means" Segment DARE GlobeNewswire
Jun-18	Dare Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 DARE GlobeNewswire
Jun-04	Dare Bioscience Announces the Upcoming Launch of Flora Sync LF5 Vaginal Probiotic Capsules DARE +6.34% GlobeNewswire
May-26	Dare Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer DARE GlobeNewswire
May-18	Dare Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies DARE GlobeNewswire
May-14	Dare Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update DARE DARE -24.13% GlobeNewswire
May-12	Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free Contraceptive DARE GlobeNewswire
May-07	Dare Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026 DARE -7.91% GlobeNewswire
Mar-26	Dare Bioscience Reports Full Year 2025 Financial Results and Provides Business Update DARE +7.86% GlobeNewswire
Mar-23	On National Viagra Day, Women Finally Claim Their Turn: DARE GlobeNewswire
Mar-20	Dare Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 DARE GlobeNewswire
Mar-16	Dare Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth DARE GlobeNewswire
Mar-12	Dare Bioscience Participates in Virtual Investor "What This Means" Segment DARE GlobeNewswire
Feb-23	Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer DARE GlobeNewswire
Feb-11	Telehealth Now Available for DARE to PLAY Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women DARE GlobeNewswire
Dec-10	DARE to PLAY Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility DARE +6.99% GlobeNewswire
Dec-01	Dare Bioscience Announces Return of Rights to Ovaprene; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization DARE -9.24% GlobeNewswire
Nov-24	Dare Bioscience Receives $3.6 Million in Additional Grant Funding DARE +6.55% GlobeNewswire
Nov-13	Dare Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update DARE GlobeNewswire
Nov-11	Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health DARE +6.59% GlobeNewswire
Nov-06	Dare Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 DARE GlobeNewswire
Nov-03	Dare Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment DARE GlobeNewswire
Oct-06	Dare Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders DARE GlobeNewswire
Sep-24	Dare Bioscience to Receive up to $499,000 to Support Preeclampsia Research DARE GlobeNewswire
Aug-14	Dare Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update DARE DARE +6.28% GlobeNewswire
Aug-07	Dare Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 DARE -9.73% GlobeNewswire
Jul-29	Dare Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY Sildenafil Cream DARE GlobeNewswire
Jul-21	UPDATE - Dare Bioscience to Host August 6 Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar DARE +6.35% GlobeNewswire
Jul-21	Dare Bioscience to Host August 6 Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar DARE +6.35% GlobeNewswire
Jul-14	Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free Contraceptive DARE +22.86% GlobeNewswire
Jul-11	Dare Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders DARE +5.23% GlobeNewswire
Jun-12	Dare Bioscience Announces Adjournment of Annual Meeting of Stockholders DARE GlobeNewswire
Jun-04	Dare Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Dare's DARE to PLAY Sildenafil Cream DARE GlobeNewswire
May-13	Dare Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update DARE GlobeNewswire
May-06	Dare Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025 DARE GlobeNewswire

Daré Bioscience, Inc.

Recent Articles by Daré Bioscience, Inc.

Upgrade your Finviz experience